Claims
- 1. An isolated, recombinant polypeptide comprising a member selected from the group consisting of:
(a) the amino acid sequence SEQ ID NO:4; and (b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO:4; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:4.
- 2. The isolated, recombinant polypeptide of claim 1, wherein the polypeptide is according to (a).
- 3. The isolated, recombinant polypeptide of claim 1, wherein the polypeptide is according to (b).
- 4. The isolated, recombinant polypeptide of claim 1, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:4, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:4.
- 5. The isolated, recombinant polypeptide of claim 1, wherein the isolated polypeptide consists of SEQ ID NO:4.
- 6. A fusion protein comprising the isolated, recombinant polypeptide of claim 1.
- 7. An immunogenic composition comprising the isolated, recombinant polypeptide of claim 1 and a pharmaceutically acceptable carrier.
- 8. The immunogenic composition of claim 7, wherein said immunogenic composition further comprises at least one other Moraxella catarrhalis antigen.
- 9. The isolated, recombinant polypeptide of claim 3, wherein the 15 contiguous amino acids comprise amino acids 790-804 of SEQ ID NO:4, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:4.
- 10. The isolated, recombinant polypeptide of claim 4, wherein the 20 contiguous amino acids of SEQ ID NO:2 comprise amino acids 676-691 of SEQ ID NO:4, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:4.
- 11. An isolated polypeptide consisting of the amino acid sequence SEQ ID NO:4.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9811945.6 |
Jun 1998 |
GB |
|
9905304.3 |
Mar 1999 |
GB |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application Ser. No. 09/701,711 filed Jul. 27, 2001, which is the National Stage Application of International Application No. PCT/EP99/03822, filed May 31, 1999, which claims the benefit of Great Britain Patent Application Nos. 9811945.6, filed Jun. 3, 1998 and 9905304.3, filed Mar. 8, 1999. The disclosure of these applications are herein incorporated by reference in their entirety.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09701711 |
Jul 2001 |
US |
Child |
10896725 |
Jul 2004 |
US |